Article
Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cancer treatment and research communications - 1 Jan 2022
Cannon Timothy Lewis, Randall Jamie N, Sokol Ethan S, Alexander Sonja M, Wadlow Raymond C, Winer Arthur A, Barnett Daniel M, Rayes Danny L, Nimeiri Halla S, McGregor Kimberly A
Abstract excerpt
BACKGROUND: BRAF V600E+ microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients comprise up to 10% of advanced CRC. They have a poor prognosis with a median survival typically <1 year. Despite use of multi-agent 1st line chemotherapy regimens and combination targeted therapies, outcomes are still poor. In our Institutional Molecular Tumor Board (MTB) database, we identified 3 mCRC patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
